Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia LoRusso

Showing results (161-170 of 164) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 164 results.
Nature Medicine|December 5, 2023
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trialJayesh Desai, Guzman Alonso, Se Hyun Kim, et al.
Journal of Medicinal Chemistry|March 15, 2012
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152)John A Flygare, Maureen Beresini, Nageshwar Budha, et al.
NPJ Precision Oncology|March 14, 2026
Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancerPaolo Tarantino, Se-Eun Kim, Melissa E Hughes, et al.
Nature Medicine|January 6, 2025
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialJuanita Lopez, Thomas Powles, Fadi Braiteh, et al.
Pageof 17

Showing results (161-170 of 164) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 164 results.
Nature Medicine|December 5, 2023
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trialJayesh Desai, Guzman Alonso, Se Hyun Kim, et al.
Journal of Medicinal Chemistry|March 15, 2012
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152)John A Flygare, Maureen Beresini, Nageshwar Budha, et al.
NPJ Precision Oncology|March 14, 2026
Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancerPaolo Tarantino, Se-Eun Kim, Melissa E Hughes, et al.
Nature Medicine|January 6, 2025
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialJuanita Lopez, Thomas Powles, Fadi Braiteh, et al.
Pageof 17